Skip to main content
Premium Trial:

Request an Annual Quote

Layoffs at 23andMe

23andMe has laid off about 100 employees from its consumer business, as GenomeWeb reports. It says that this represents about 14 percent of the overall 23andMe workforce.

CNBC traces this move to a decline in sales, and CEO Anne Wojcicki tells it that she was surprised by the turn in the market but notes privacy concerns could be a factor as could fears of a wider economic downturn. "This has been slow and painful for us," Wojcicki tells CNBC.

The Verge reports that other genetic testing companies have also noted a shrinking market. Illumina reported last year, it says, that there had been a decline in the direct-to-consumer genetic testing space and that Veritas Genomics recently paused its US operations and laid off staff. GenomeWeb also notes that Helix had layoffs and shifted its focus to population genomics partnerships.

Privacy has also been an increasing concern for the field, as people have become worried about how their data could be used, CNBC adds. 

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.